AXIM Biotechnologies and Verséa Ophthalmics have entered an exclusive global commercial partnership agreement for the sales and distribution of new ophthalmic diagnostics solutions.
Under the collaboration deal, Verséa will have exclusive commercial rights to AXIM’s portfolio of point-of-care (POC) lab testing readers and three important biomarker diagnostic tests.
AXIM’s biomarker tests include the Ocular Immunoglobulin E (IgE) test, the Lactoferrin test and the Matrix Metalloproteinase 9 (MMP-9) test.
They are specifically designed for the detection and quantification of biomarkers related to aqueous deficient dry eye disease and non-specific allergic conjunctivitis.
The tests require 0.5 microliters of tears and provide quantitative results in less than ten minutes.
The company’s Ocular IgE and Lactoferrin tests have already received US Food and Drug Administration (FDA) approval and both have dedicated Medicare CPT codes.
Verséa intends to launch both of the tests at the 2022 American Academy of Ophthalmology (AAO) and American Academy of Optometry (AAOPT) conferences.
The quantitative tear MMP-9 test measures the intensity of inflammation that affects dry eye patients. This enables more objective classification and management of the disease.
It is expected to be available in the next 18 to 24 months.
AXIM Biotech CEO John Huemoeller II said: “Since the development of our novel ocular diagnostic tests and subsequent success in proving their effectiveness, rather than building an internal team to commercialise the tests, we have been searching for a partner with a solid commercial infrastructure and a firm commitment to eye care, capable of bringing our tests to clinical offices on a global scale.”
The company has been preparing and is ready to support new orders related to the launch of the tests following this deal.